Grace-Marie Turner is president of the Galen Institute, a public policy research organization that she founded in 1995 to promote an informed debate over free-market ideas for health reform.
She has been instrumental in developing and promoting ideas for reform that transfer power over health care decisions to doctors and patients. She speaks and writes extensively about incentives to promote a more competitive, patient-centered marketplace in the health sector.
* Grace-Marie speaks extensively in the U.S. and abroad, including at the London School of Economics, Oxford University, and the Gregorian University at the Vatican in Rome.
* She testifies regularly before Congress and advises senior government officials, governors, and state legislators on health policy.
* Grace-Marie served for a three-year term as a member of the National Advisory Council of Healthcare Research and Quality and served as a member of the Medicaid Commission, charged with making recommendations to modernize and improve Medicaid.
Grace-Marie is founder and facilitator of the Health Policy Consensus Group which serves as a forum for analysts from market-oriented think tanks around the country to analyze and develop policy recommendations. She is the editor of Empowering Health Care Consumers through Tax Reform and produces a widely-read weekly electronic newsletter, Health Policy Matters. She has been published in major newspapers, including The Wall Street Journal and USA Today, she has appeared on ABC’s 20/20 and on hundreds of radio and television programs in the U.S. She also received the 2007 Outstanding Achievement Award for Promotion of Consumer Driven Health Care from Consumer Health World.
In the mid-1990s, Grace-Marie served as executive director of the National Commission on Economic Growth and Tax Reform. For 12 years, she was president of Arnett & Co., a health policy analysis and communications firm. Her early career was in politics and journalism, where she received numerous awards for her writings on politics and economics.
The agency that runs the Medicare program decided in late March that it will pay for patients to receive an advanced new treatment for prostate cancer called Provenge.
The United States is the world’s leader in pharmaceutical innovation, especially in the newest form of drugs created through biomedical research.
The White House and its allies have just begun a multi-million dollar public relations effort – funded in large part by taxpayers – to try to convince senior citizens that ObamaCare is good for them.
Many Americans wondered why Congress was in such a rush to take the final vote on ObamaCare at midnight on a Sunday night when most of its major programs don’t begin until 2014. It’s now clear that Democratic leaders feared their members might balk if they saw the objective analysis that was being prepared showing the overhaul law’s true costs.
Questions are rightly being raised about whether actress Natasha Richardson could have been saved if her skiing accident had occurred in the U.S. rather than in Canada.